tiprankstipranks
FDA Approves AstraZeneca’s (NASDAQ:AZN) Lung Cancer Combination Treatment
Market News

FDA Approves AstraZeneca’s (NASDAQ:AZN) Lung Cancer Combination Treatment

Story Highlights

AstraZeneca’s non-small cell lung cancer combination treatment of Imjudo, Imfinzi and chemotherapy has bagged the U.S. FDA’s approval.

U.K.-based drugmaker AstraZeneca’s (NASDAQ:AZN) metastatic non-small cell lung cancer treatment, which is a combination of Imjudo and Imfinzi along with platinum-based chemotherapy, has been approved by the U.S. Food and Drug Administration (FDA).

Positive results of the POSEIDON phase 3 trial supported the regulator’s approval. Under this trial, the patients received treatment until the disease progressed or reached an unacceptable toxicity level.

Further, in comparison to patients treated with a range of chemotherapy options, patients given the above-mentioned combined treatment showed a 23% lower death risk. Also, the approved treatment witnessed an estimated 33% survival rate at two years against 22% in patients with just chemotherapy.

What is the Target Price for AZN Stock?

The average AstraZeneca price target of $75 implies an upside potential of 15.23%. AZN stock has a Moderate Buy consensus rating based on one Buy.

For the U.K.-listed AstraZeneca (LSE:AZN) stock, analysts are cautiously optimistic, with a Moderate Buy consensus rating based on nine Buys, five Holds and one Sell.

Disclosure

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles